For US Healthcare Professionals Only

Beyfortus® (nirsevimab-alip) 50 mg and 100 mg Injection for Your Practice

Order Beyfortus Packaging Image

Start Planning for the 2024/2025 Season Today

Product images are representative of scale - actual size of packaging may be different.

How Beyfortus is supplied¹

Beyfortus injection is a sterile, preservative-free, clear to opalescent, colorless to yellow solution supplied as follows:

• Five 50 mg/0.5 mL single-dose pre-filled syringes in a carton: NDC 49281-575-15
• Five 100 mg/mL single-dose pre-filled syringes in a carton: NDC 49281-574-15

Each Beyfortus pre-filled syringe is for one-time use only.

Only 5-pack cartons will be available in the US at this time.
Order Beyfortus Packaging Image
Product images are representative of scale - actual size of packaging may be different.
Additional ordering details:

• Extended payment terms: 2% Prompt Pay 150, net 151 days
• All offers valid on orders received through March 31, 2024
• Product is fully returnable upon expiration
Reference: 1. Beyfortus (nirsevimab-alip). Prescribing Information. Sanofi.

Indication

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Important safety information

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see full Prescribing Information.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.